Innovation Map Houston – Houston Oncology Therapeutics Company Raises 11.4M in Seed Funding
August 27, 2024
News & Publications
In The News
BioWorld – Diakonos Raises $11.4M for Its Dendritic Cell Vaccine
August 27, 2024
Oncology Nursing News – FDA Grants Fast Track Status to Dendritic Cell Vaccine for Pancreatic Cancer
July 23, 2024
CureToday.com – FDA Fast Tracks Pancreatic Cancer Vaccine
July 19, 2024
Vaccine Nation – Diakonos Announces FDA Fast Track Designation for DCV
July 18, 2024
Press Releases
Diakonos Oncology to Present at Biotech Showcase 2025
April 1, 2025
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer
November 18, 2024
Neurosurgeon Joseph Georges, P.I. for Diakonos Oncology’s Phase 1 Trial of Its Unique Dendritic Cell Vaccine for Gliobastoma, Receives the CNS 2024 Rosenblum-Mahaley Clinical Research Award
October 15, 2024
CNS 2024 Conference Presentation: Diakonos Oncology’s Autologous Dendritic Cell Vaccine (DOC1021) Yields 93% 12-Month Survival for Glioblastoma Patients
October 1, 2024
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial
August 26, 2024
Company Presentations
SNO 2024 Presentation: DOC1021 Cell-Based Vaccination as Adjuvant Therapy for Glioblastoma: Phase I Clinical Trial Analysis
November 22, 2024
SITC 2024 Poster: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Correlation of Immune Response and Early Efficacy Signal with Vaccine Cell Gene Signature
November 9, 2024
CNS 2024 Presentation: Vaccination by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Analysis of Phase I Results
September 30, 2024
AACR 2024 Poster: Vaccine Immunotherapy by Homologous Antigenic Loading as Adjuvant Therapy for Glioblastoma: Ongoing Phase 1 Analysis
April 9, 2024
Publications
Science Translational Medicine: A Unique Subset of Cytotoxic Effector Memory T-cells Enhances CAR T-cell Function against Pancreatic Ductal Adenocarcinoma. Konduri V, Joseph S, Byrd TT, et al.
May 5, 2022
FASEB Journal: MHC class I and II peptide homology regulates the cellular immune response. FASEB. Halpert MM, Konduri V, Liang D, et al.
April 16, 2020
Cancer Gene Therapy: Dendritic cell vaccination plus low-dose Doxorubicin for the treatment of spontaneous canine hemangiosarcoma. Konduri V*, Halpert MM*, et al. Cancer Gene Therapy.
January 23, 2019
Frontiers in Immunology: AIMp1 Potentiates TH1 polarization and is critical for effective antitumor and antiviral immunity. Liang D, Tian L, You R, et al.
January 15, 2018
OncoImmunology: Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma. Oncoimmunology. Konduri V, Li D, Halpert MM, et al.
July 22, 2016